Shots:
- Teva & Fosun Pharma have partnered to advance the development of TEV-56278 in immuno-oncology & accelerate global clinical data generation
- As per the deal, Fosun will receive an exclusive license to develop, manufacture & commercialize TEV-56278 in mainland China, Hong Kong SAR, Macau SAR & Taiwan as well as select Southeast Asian countries, while Teva will retain rights in the rest of the world; financial terms remain undisclosed
- TEV-56278, an anti-PD-1 antibody-cytokine fusion protein, delivers IL-2 (ATTENUKINE) selectively to PD-1+ T cells in the tumor microenvironment to increase anti-tumor activity with reduced systemic toxicity, plus it is being studied in P-I trial to treat multiple cancer types, incl. melanoma
Ref: GlobeNewswire | Image: Teva and Fosun Pharma | Press Release
Related News:- Teva and Alvotech’s Selarsdi (Biosimilar, Stelara) Receives the US FDA’s Interchangeability Designation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
